8-K Announcements
6Material company update
Nov 5, 2026·SEC
Material company update
Apr 28, 2026·SEC
Material company update
Mar 12, 2026·SEC
Cassava Sciences remains a high-risk, pre-revenue biotechnology firm entirely dependent on the successful clinical validation of its lead candidate, Simufilam.
Price trend, volume and key moving averages
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2025Latest Nov 12, 2025 | -$0.22+18.5% vs -$0.27 | — vs — |
Q3 2025 Aug 14, 2025 | -$0.18 vs — | — vs — |
Q2 2025 May 8, 2025 | -$0.48 vs — | — vs — |
Q2 2025 Mar 3, 2025 | -$0.57+16.2% vs -$0.68 | — vs — |
Benchmark FLNA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Filana Therapeutics, Inc. (FLNA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.45 | $21.87M | -0.52 | — | — | -63.91% | — | |
| $21.23 | $3.64B | 10.28 | 11.87% | 30.13% | 28.03% | — | |
| $277.62 | $7.74B | -23.85 | -100% | — | -34.15% | — | |
| $1.43 | $44.87M | 3.97 | — | 32.23% | 83.42% | — | |
| $1.15 | $106.57M | -4.37 | — | — | -21.11% | — | |
| $2.23 | $226.96M | -5.05 | -86.92% | -181.94% | -104.05% | — |
Filana Therapeutics, Inc. (FLNA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Filana Therapeutics, Inc. (FLNA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 5, 2026·SEC
Apr 28, 2026·SEC
Mar 12, 2026·SEC
Get notified when FLNA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Filana Therapeutics, Inc. (FLNA) stock FAQ — growth, dividends, profitability & financials explained
No. Filana Therapeutics, Inc. (FLNA) reported a net loss of $42.2M over the trailing twelve months.
Filana Therapeutics, Inc. (FLNA) had a return on equity (ROE) of -63.9% over the trailing twelve months. A negative ROE means the company lost money over the period.
Filana Therapeutics, Inc. (FLNA) had negative free cash flow of $32.8M in fiscal year 2025.